Behavioral: 50 patients will have a Free Choice between Filgotinib and anti TNF ( DrugBank: Filgotinib )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04985435 (ClinicalTrials.gov) | May 12, 2021 | 19/7/2021 | Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH) | Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in Patients With Active Rheumatoid Arthritis (BACH) | Rheumatoid Arthritis | Drug: Filgotinib;Drug: Anti-Tumor Necrosis Factor Alpha Drug (Product);Behavioral: 50 patients will have a Free Choice between Filgotinib and anti TNF | R.Bos | Galapagos NV;Medical Centre Leeuwarden;Leiden University Medical Center | Recruiting | 18 Years | 101 Years | All | 100 | Phase 4 | Netherlands |